0.88Open0.95Pre Close1 Volume166 Open Interest2.50Strike Price88.00Turnover1032.50%IV0.00%PremiumJan 17, 2025Expiry Date0.88Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.3565Delta0.1682Gamma1.06Leverage Ratio-0.0679Theta-0.0003Rho-0.38Eff Leverage0.0008Vega
ProKidney Stock Discussion
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Positive
FDA confirmation that PROACT 1 Phase 3 study could be sufficient for full regulatory approval
Accelerated approval pathway available with eGFR slope as surrogate endpoint
Strong cash position of $406.8 million, supporting operations into 2027
Reduced R&D expenses by $0.9 million year-over-year
Slight improvement...
SEC· 11 mins ago
ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S. Believes Phase 3 Regen-016 (Proact 2) Trial Is Not Required for Initial U.S. Registration
No comment yet